Iterum Therapeutics plc (ITRM) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Dublin, Ireland. El CEO actual es Corey N. Fishman.
ITRM tiene fecha de IPO 2018-05-25, 9 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.6M.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
